• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function.左氧氟沙星在急性住院的不同程度肾功能老年患者中的群体药代动力学和药效学
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02134-16. Print 2017 Mar.
2
Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.超重和肥胖成年患者使用利奈唑胺的群体药代动力学和剂量考虑因素。
Clin Pharmacokinet. 2018 Aug;57(8):989-1000. doi: 10.1007/s40262-017-0606-5.
3
Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin.口服左氧氟沙星的群体药代动力学和药效学建模
J Med Assoc Thai. 2018 Aug;99(8):886-92.
4
Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.严重病态肥胖患者(体重指数≥40 kg/m²)的左氧氟沙星给药方案应以基于理想体重的肌酐清除率估计值为指导,并通过治疗药物监测进行优化。
Clin Pharmacokinet. 2014 Aug;53(8):753-62. doi: 10.1007/s40262-014-0154-1.
5
Oral levofloxacin: population pharmacokinetics model and pharmacodynamics study in bone and joint infections.口服左氧氟沙星:骨与关节感染的群体药代动力学模型及药效学研究
J Antimicrob Chemother. 2022 Apr 27;77(5):1344-1352. doi: 10.1093/jac/dkac031.
6
[Study of pharmacokinetics/pharmacodynamics of levofloxacin].左氧氟沙星的药代动力学/药效学研究
Zhonghua Yi Xue Za Zhi. 2005 Jul 20;85(27):1926-32.
7
Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers.左氧氟沙星对肉鸡大肠杆菌的体外抗菌活性及其静脉注射和口服给药后的药代动力学特征
Res Vet Sci. 2017 Jun;112:26-33. doi: 10.1016/j.rvsc.2017.01.003. Epub 2017 Jan 12.
8
Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.多黏菌素肺部给药在小鼠肺部感染模型中对铜绿假单胞菌的药代动力学/药效学研究
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02025-16. Print 2017 Mar.
9
Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study.左氧氟沙星和莫西沙星药物依从性差对呼吸道感染抗菌疗效的影响:药代动力学/药效学模拟研究。
Int J Antimicrob Agents. 2015 Jan;45(1):79-83. doi: 10.1016/j.ijantimicag.2014.08.011. Epub 2014 Oct 5.
10
Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.不同年龄羊驼幼崽静脉注射马波沙星后的药代动力学评价,以及蒙特卡洛模拟的药代动力学/药效学分析。
J Vet Pharmacol Ther. 2018 Dec;41(6):861-870. doi: 10.1111/jvp.12698. Epub 2018 Jul 18.

引用本文的文献

1
Pharmacokinetic Equations Applied to Obtain New Topological Models in the Search of Antibacterial Compounds.应用药代动力学方程以获取用于寻找抗菌化合物的新拓扑模型。
Pharmaceuticals (Basel). 2025 Jun 10;18(6):865. doi: 10.3390/ph18060865.
2
Development of a Population Pharmacokinetic Model of Levofloxacin in Healthy Adults and Identification of Optimal Dosing Regimens.健康成年人左氧氟沙星群体药代动力学模型的建立及最佳给药方案的确定。
Pharmaceuticals (Basel). 2025 Apr 25;18(5):621. doi: 10.3390/ph18050621.
3
An insight into pharmacokinetics and dose optimization of antimicrobials agents in elderly patients.老年患者抗菌药物的药代动力学及剂量优化研究
Front Pharmacol. 2024 Sep 30;15:1396994. doi: 10.3389/fphar.2024.1396994. eCollection 2024.
4
Pharmacokinetics of Antibacterial Agents in the Elderly: The Body of Evidence.老年人抗菌药物的药代动力学:证据主体
Biomedicines. 2023 Jun 4;11(6):1633. doi: 10.3390/biomedicines11061633.
5
Infant Exposure to Antituberculosis Drugs via Breast Milk and Assessment of Potential Adverse Effects in Breastfed Infants: Critical Review of Data.婴儿通过母乳接触抗结核药物及母乳喂养婴儿潜在不良反应的评估:数据的批判性综述
Pharmaceutics. 2023 Apr 13;15(4):1228. doi: 10.3390/pharmaceutics15041228.
6
Factors Contributing to Chronic Kidney Disease following COVID-19 Diagnosis in Pre-Vaccinated Hospitalized Patients.新冠疫苗接种前住院患者确诊新冠后导致慢性肾病的因素。
Vaccines (Basel). 2023 Feb 13;11(2):433. doi: 10.3390/vaccines11020433.
7
Analysis of the Distribution and Drug Resistance of Pathogens in Patients with Urinary Tract Infection in the Eastern Chongming Area of Shanghai from 2018 to 2020.2018年至2020年上海崇明东部地区尿路感染患者病原菌分布及耐药性分析
Infect Drug Resist. 2022 Nov 1;15:6413-6422. doi: 10.2147/IDR.S384515. eCollection 2022.
8
Ciprofloxacin in Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): A Population Pharmacokinetic Study.接受体外膜肺氧合(ECMO)治疗患者的环丙沙星:一项群体药代动力学研究。
Pharmaceutics. 2022 Apr 29;14(5):965. doi: 10.3390/pharmaceutics14050965.
9
Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability.泌尿系统感染中氟喹诺酮类药物有效个体化给药的关键因素:个体间药代动力学和药效学变异性
Antibiotics (Basel). 2022 May 11;11(5):641. doi: 10.3390/antibiotics11050641.
10
Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients.住院成年患者左氧氟沙星静脉给药的群体药代动力学和剂量优化。
Sci Rep. 2022 May 27;12(1):8930. doi: 10.1038/s41598-022-12627-1.

本文引用的文献

1
Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?氟喹诺酮类药物相关性肌腱病:左氧氟沙星的风险最大吗?
Pharmacotherapy. 2016 Jun;36(6):679-93. doi: 10.1002/phar.1761. Epub 2016 Jun 11.
2
Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system.氟喹诺酮类药物相关肌腱断裂:美国食品药品监督管理局不良事件报告系统中的报告总结
Expert Opin Drug Saf. 2015;14(11):1653-60. doi: 10.1517/14740338.2015.1085968. Epub 2015 Sep 22.
3
Population pharmacokinetics of levofloxacin in Korean patients.左氧氟沙星在韩国患者中的群体药代动力学。
J Chemother. 2016 Aug;28(4):308-13. doi: 10.1179/1973947815Y.0000000033.
4
Adverse drug reactions in special populations - the elderly.特殊人群中的药物不良反应——老年人
Br J Clin Pharmacol. 2015 Oct;80(4):796-807. doi: 10.1111/bcp.12596. Epub 2015 May 22.
5
Impact of levofloxacin dose adjustments by dispensing pharmacists on adverse reactions and costs in the treatment of elderly patients.调剂药师调整左氧氟沙星剂量对老年患者治疗中不良反应及费用的影响。
Pharmazie. 2013 Dec;68(12):977-82.
6
GFR estimation using the Cockcroft-Gault, MDRD study, and CKD-EPI equations in the elderly.在老年人中使用Cockcroft-Gault公式、MDRD研究公式和CKD-EPI公式估算肾小球滤过率
Am J Kidney Dis. 2012 Nov;60(5):847-9. doi: 10.1053/j.ajkd.2012.08.001. Epub 2012 Aug 30.
7
Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.使用 Pmetrics 进行离群值和亚群的准确检测,这是一个用于 R 的非参数和参数药物计量学建模和模拟软件包。
Ther Drug Monit. 2012 Aug;34(4):467-76. doi: 10.1097/FTD.0b013e31825c4ba6.
8
Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations.运用药代动力学建模和蒙特卡罗模拟评估老年患者中氟喹诺酮类药物的降低剂量方案。
J Antimicrob Chemother. 2012 Sep;67(9):2207-12. doi: 10.1093/jac/dks195. Epub 2012 May 30.
9
Levofloxacin in the treatment of community-acquired pneumonia.左氧氟沙星治疗社区获得性肺炎。
Expert Rev Anti Infect Ther. 2010 May;8(5):505-14. doi: 10.1586/eri.10.35.
10
Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis.左氧氟沙星治疗复杂性尿路感染的微生物学结局:药代动力学/药效学分析。
Int J Antimicrob Agents. 2010 Jun;35(6):573-7. doi: 10.1016/j.ijantimicag.2010.02.004. Epub 2010 Mar 11.

左氧氟沙星在急性住院的不同程度肾功能老年患者中的群体药代动力学和药效学

Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function.

作者信息

Cojutti Pier Giorgio, Ramos-Martin Virginia, Schiavon Isabella, Rossi Paolo, Baraldo Massimo, Hope William, Pea Federico

机构信息

Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, Udine, Italy.

Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy.

出版信息

Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02134-16. Print 2017 Mar.

DOI:10.1128/AAC.02134-16
PMID:28031199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5328580/
Abstract

A retrospective study was conducted in a large sample of acutely hospitalized older patients who underwent therapeutic drug monitoring during levofloxacin treatment. The aim was to assess the population pharmacokinetics (popPK) and pharmacodynamics of levofloxacin among older patients. PopPK and Monte Carlo simulation were performed to define the permissible doses in older patients according to various degrees of renal function. Classification and regression tree (CART) analysis was used to detect the cutoff 24-hour area under the concentration-time curve (AUC)/MIC ratio that best correlated with the clinical outcome. The probability of target attainment (PTA) of this value was calculated against different pathogens. A total of 168 patients were included, and 330 trough and 239 peak concentrations were used for the popPK analysis. Creatinine clearance (CrCL) was the only covariate that improved the model fit (levofloxacin CL = 0.399 + 0.051 × CrCL [creatinine clearance estimated by means of the chronic kidney disease epidemiology]). Drug doses ranged between 500 mg every 48 h and 500 mg every 12 h in relation to different renal functions. The identified cutoff AUC/MIC ratio (≥95.7) was the only covariate that correlated with a favorable clinical outcome in multivariate regression analysis (odds ratio [OR], 20.85; 95% confidence interval [CI], 1.56 to 186.73). PTAs were optimal (>80%) against and , borderline against , and suboptimal against The levofloxacin doses defined in our study may be effective for the treatment of infections due to bacterial pathogens, with an MIC of ≤0.5 mg/liter in older patients with various degrees of renal function, while minimizing the toxicity risk. Conversely, the addition of another active antimicrobial should be considered whenever treating infections caused by less susceptible pathogens.

摘要

对一大群急性住院的老年患者进行了一项回顾性研究,这些患者在左氧氟沙星治疗期间接受了治疗药物监测。目的是评估老年患者中左氧氟沙星的群体药代动力学(popPK)和药效学。进行了群体药代动力学和蒙特卡洛模拟,以根据不同程度的肾功能确定老年患者的允许剂量。使用分类与回归树(CART)分析来检测与临床结果最相关的24小时浓度-时间曲线下面积(AUC)/最低抑菌浓度(MIC)比值的临界值。针对不同病原体计算该值的目标达成概率(PTA)。共纳入168例患者,330个谷浓度和239个峰浓度用于群体药代动力学分析。肌酐清除率(CrCL)是唯一能改善模型拟合度的协变量(左氧氟沙星清除率CL = 0.399 + 0.051×CrCL [采用慢性肾脏病流行病学方法估算的肌酐清除率])。根据不同的肾功能,药物剂量范围为每48小时500毫克至每12小时500毫克。在多变量回归分析中,确定的临界AUC/MIC比值(≥95.7)是唯一与良好临床结果相关的协变量(优势比[OR],20.85;95%置信区间[CI],1.56至186.73)。针对肺炎链球菌和金黄色葡萄球菌的PTA最佳(>80%),针对肺炎克雷伯菌的PTA处于临界值,针对铜绿假单胞菌的PTA欠佳。我们研究中确定的左氧氟沙星剂量可能对治疗由细菌病原体引起的感染有效,对于不同程度肾功能的老年患者,当MIC≤0.5毫克/升时,同时将毒性风险降至最低。相反,在治疗由较不敏感病原体引起的感染时,应考虑加用另一种活性抗菌药物。